CRISPR Therapeutics AG (CRSP) Balance Sheet
CRSP balance sheet, 2025
December 31, 2025 · U.S. dollars$2.27B assets = $343.4M liabilities + $1.92B equity
Both columns are drawn to the same scale: what CRSP owns equals what it owes plus shareholders’ equity. Hover a block for its value.
CRSP financial health
Descriptive bands, not a rating. Fiscal 2025.
CRSP balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $345.0M2016 | $2.27B2025 | +23.3%/yr | |
| Total liabilities | $112.1M2016 | $343.4M2025 | +13.2%/yr | |
| Shareholders’ equity | $232.8M2016 | $1.92B2025 | +26.4%/yr | |
| Cash & short-term investments | $315.5M2016 | $1.98B2025 | +22.6%/yr | |
| Total debt | $60.3M2016 | $394.9M2025 | +23.2%/yr | |
| Net cash (debt) | $255.2M2016 | $1.58B2025 | +$1.3B | |
| Working capital | $298.2M2016 | $1.84B2025 | +$1.5B | |
| Book value per share | $4.692017 | $21.372025 | +20.9%/yr | |
| Debt / equity | 0.262016 | 0.212025 | −0.05 | |
| Shares outstanding | 40.1M2017 | 89.9M2025 | +10.6%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CRSP assets
CRSP liabilities and equity
CRSP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
CRSP balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $1.98B | $1.90B | $1.69B | $1.82B | $2.38B | $1.69B | $943.8M | $456.6M | $239.8M | $315.5M |
| Cash & equivalents | $355.2M | $298.3M | $389.5M | $211.9M | $923.0M | $1.17B | $943.8M | $456.6M | $239.8M | $315.5M |
| Short-term investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $521.7M | — | — | $0 | $0 |
| Receivables | $0 | $25.0M | $200.0M | $11.2M | $305,000 | $10.8M | $99,000 | $88,000 | $2.6M | $3.2M |
| Inventory | $0 | $0 | $0 | −$11.2M | $0 | $0 | $1 | $1 | $1 | $0 |
| Other current assets | $9.8M | $8.3M | $14.4M | $37.7M | $38.1M | $15.4M | $43.7M | $9.7M | $6.0M | $1.5M |
| Total current assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $987.5M | $466.4M | $248.4M | $320.2M |
| Property, plant & equipment (net) | $247.6M | $277.6M | $305.9M | $320.6M | $312.0M | $93.0M | $72.8M | $18.5M | $18.9M | $21.0M |
| Goodwill & intangible assets | $0 | $0 | $16,000 | $71,000 | $125,000 | $180,000 | $235,000 | $289,000 | $344,000 | $399,000 |
| Long-term investments | $0 | $0 | $2.0M | $53.1M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $32.0M | $27.3M | $13.6M | $16.3M | $22.2M | $18.1M | $6.1M | $3.8M | $3.8M | $3.3M |
| Total assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489.0M | $271.3M | $345.0M |
| Liabilities | ||||||||||
| Accounts payable | $11.1M | $14.7M | $38.1M | $27.4M | $14.8M | $9.1M | $5.9M | $5.1M | $1.6M | $4.6M |
| Short-term debt | $18.6M | $17.3M | $15.6M | $15.8M | $12.2M | $11.4M | $8.5M | $35.3M | $44.2M | $60.3M |
| Deferred revenue | $15.8M | $3.8M | $4.1M | $12.3M | $1.0M | $2.3M | $960,000 | $57.8M | $56.9M | $77.6M |
| Total current liabilities | $149.1M | $87.8M | $108.8M | $121.1M | $119.9M | $94.3M | $57.1M | $27.7M | $14.5M | $22.0M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $206.7M | $223.7M | $238.6M | $244.0M | $225.0M | $61.4M | $52.5M | — | — | — |
| Other long-term liabilities | $194.3M | $222.2M | $238.0M | $246.5M | $232.5M | $69.5M | $70.2M | $69.1M | $69.0M | $90.1M |
| Total liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M | $163.7M | $127.3M | $96.8M | $83.5M | $112.1M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $3.1M | $2.7M | $2.5M | $2.4M | $2.4M | $2.3M | $1.8M | $1.6M | $313.3M | $289.6M |
| Retained earnings (deficit) | −$1.95B | −$1.37B | −$999.7M | −$846.1M | −$195.9M | −$573.6M | −$224.7M | −$291.6M | −$125.4M | −$57.1M |
| Treasury stock | — | — | — | −$63,000 | −$63,000 | −$63,000 | −$63,000 | −$57,000 | $0 | $0 |
| Accumulated other comprehensive income | $4.8M | $1.8M | $1.9M | −$15.6M | −$5.1M | −$83,000 | $7,000 | −$8,000 | $14,000 | −$26,000 |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939.4M | $392.2M | $187.8M | $232.8M |
| Key figures | ||||||||||
| Total debt | $394.9M | $223.7M | $238.6M | $244.0M | $225.0M | $61.4M | $52.5M | $35.3M | $44.2M | $60.3M |
| Net cash (debt) | $1.58B | $1.68B | $1.46B | $1.57B | $2.15B | $1.63B | $891.2M | $421.3M | $195.6M | $255.2M |
| Working capital | $1.84B | $1.85B | $1.80B | $1.73B | $2.30B | $1.62B | $930.4M | $438.6M | $233.9M | $298.2M |
| Tangible book value | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939.2M | $391.9M | $187.5M | $232.4M |
| Book value per share | $21.37 | $22.90 | $23.77 | $24.12 | $29.85 | $25.23 | $16.50 | $8.18 | $4.69 | — |
| Shares outstanding | 89.9M | 84.4M | 79.2M | 77.7M | 80.4M | 65.9M | 56.9M | 48.0M | 40.1M | — |
| Current ratio | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Quick ratio | 13.25 | 21.97 | 17.41 | 15.08 | 19.85 | 18.05 | 16.53 | 16.46 | 16.70 | 14.49 |
| Debt / equity | 0.21 | 0.12 | 0.13 | 0.13 | 0.09 | 0.04 | 0.06 | 0.09 | 0.24 | 0.26 |
| Equity / assets | 84.8% | 86.2% | 84.4% | 83.6% | 87.2% | 91.0% | 88.1% | 80.2% | 69.2% | 67.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $2.36B | $2.44B | $1.98B | $1.92B | $1.72B | $1.86B | $1.90B | $1.94B | $2.00B | $2.11B | $1.69B | $1.74B |
| Cash & equivalents | $291.3M | $423.3M | $355.2M | $290.0M | $197.1M | $235.2M | $298.3M | $225.7M | $484.5M | $707.4M | $389.5M | $527.8M |
| Short-term investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | $1.30B | $1.21B |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $25.0M | $0 | $0 | $0 | $200.0M | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $7.4M | $6.6M | $0 | $13.4M | $8.9M | $12.3M | $8.3M | $8.2M | $8.8M | $11.5M | $14.4M | $20.8M |
| Total current assets | $2.37B | $2.45B | $1.98B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | $1.91B | $1.76B |
| Property, plant & equipment (net) | $233.7M | $240.8M | $247.6M | $255.5M | $262.6M | $269.7M | $277.6M | $284.8M | $291.6M | $298.5M | $305.9M | $312.3M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2,000 | $16,000 | $30,000 |
| Long-term investments | $0 | $0 | $0 | $28.4M | $0 | $0 | $0 | $0 | $11.2M | $0 | $2.0M | $0 |
| Other non-current assets | $45.3M | $36.6M | $41.8M | $32.3M | $33.5M | $28.8M | $27.3M | $27.4M | $26.7M | $20.9M | $13.6M | $13.9M |
| Total assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | $2.23B | $2.09B |
| Liabilities | ||||||||||||
| Accounts payable | $11.3M | $13.6M | $11.1M | $11.8M | $9.8M | $13.1M | $14.7M | $15.6M | $9.5M | $16.5M | $38.1M | $26.2M |
| Short-term debt | $18.6M | $18.6M | $18.6M | $18.3M | $18.0M | $17.5M | $17.3M | $16.9M | $16.5M | $16.0M | $15.6M | $15.0M |
| Deferred revenue | $15.2M | $15.3M | $15.8M | $1.3M | $2.1M | $3.0M | $3.8M | $4.5M | $4.8M | $4.1M | $4.1M | $3.5M |
| Total current liabilities | $132.9M | $136.3M | $149.1M | $119.0M | $104.4M | $119.4M | $87.8M | $89.8M | $127.8M | $119.0M | $108.8M | $111.2M |
| Long-term debt | $586.2M | $585.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $197.6M | $202.2M | $206.7M | $211.0M | $215.5M | $219.4M | $223.7M | $227.5M | $231.3M | $234.9M | $238.6M | $241.6M |
| Other long-term liabilities | $185.1M | $189.5M | $194.3M | $210.4M | $214.2M | $217.5M | $222.2M | $226.7M | $231.1M | $236.1M | $238.0M | $247.8M |
| Total liabilities | $904.2M | $911.3M | $343.4M | $329.3M | $318.6M | $336.9M | $310.0M | $316.5M | $358.9M | $355.1M | $346.8M | $359.0M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $3.1M | $3.1M | $3.1M | $3.0M | $2.8M | $2.7M | $2.7M | $2.7M | $2.7M | $2.7M | $2.5M | $2.5M |
| Retained earnings (deficit) | −$2.16B | −$2.07B | −$1.95B | −$1.82B | −$1.71B | −$1.50B | −$1.37B | −$1.33B | −$1.24B | −$1.12B | −$999.7M | −$1.09B |
| Accumulated other comprehensive income | −$4.6M | −$1.9M | $4.8M | $5.0M | $4.0M | $4.1M | $1.8M | $10.6M | −$2.9M | −$1.6M | $1.9M | −$6.8M |
| Total shareholders' equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B |
| Key figures | ||||||||||||
| Total debt | $783.7M | $787.6M | $394.9M | $403.8M | $215.5M | $219.4M | $223.7M | $227.5M | $231.3M | $234.9M | $238.6M | $241.6M |
| Net cash (debt) | $1.58B | $1.65B | $1.58B | $1.51B | $1.51B | $1.64B | $1.68B | $1.71B | $1.77B | $1.87B | $1.46B | $1.50B |
| Working capital | $2.24B | $2.31B | $1.83B | $1.81B | $1.63B | $1.75B | $1.85B | $1.85B | $1.88B | $2.00B | $1.80B | $1.65B |
| Tangible book value | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B |
| Book value per share | $18.10 | $18.89 | $21.37 | $20.98 | $19.65 | $21.28 | $22.61 | $22.76 | $23.33 | $25.48 | $23.15 | $21.76 |
| Shares outstanding | 96.5M | 96.1M | 89.9M | 91.3M | 87.1M | 85.9M | 85.5M | 85.2M | 84.9M | 81.8M | 81.3M | 79.4M |
| Current ratio | 17.85 | 17.96 | 13.25 | 16.22 | 16.61 | 15.64 | 22.07 | 21.64 | 15.73 | 17.81 | 17.54 | 15.83 |
| Quick ratio | 17.79 | 17.92 | 13.25 | 16.10 | 16.53 | 15.53 | 21.97 | 21.55 | 15.66 | 17.72 | 17.41 | 15.64 |
| Debt / equity | 0.45 | 0.43 | 0.21 | 0.21 | 0.13 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 | 0.13 | 0.14 |
| Equity / assets | 65.9% | 66.6% | 84.8% | 85.3% | 84.3% | 84.4% | 86.2% | 86.0% | 84.7% | 85.4% | 84.4% | 82.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 12, 2026); data from EODHD.
CRSP financial position
At the end of fiscal 2025 (December 31, 2025), CRISPR Therapeutics had total assets of $2.3 billion (up 1.0% from a year earlier), total liabilities of $343.4 million and shareholders' equity of $1.9 billion. It held $2.0 billion in cash and short-term investments against $394.9 million of debt, a net cash position of $1.6 billion. Its current ratio was 13.32. In the latest quarter (ended June 30, 2026) total assets were $2.7 billion and equity $1.7 billion.
Related: CRSP income statement, CRSP cash flow statement, CRSP key metrics. See the CRSP stock overview for the latest quote and news.
CRSP balance sheet FAQ
What are CRISPR Therapeutics's total assets?
CRISPR Therapeutics reported total assets of $2.3 billion at the end of fiscal 2025 (December 31, 2025), compared with $2.2 billion a year earlier.
How much debt does CRISPR Therapeutics have?
CRISPR Therapeutics had $394.9 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.21.
How much cash does CRISPR Therapeutics have?
CRISPR Therapeutics held $2.0 billion in cash and short-term investments at the end of fiscal 2025; with $394.9 million of debt that is net cash of $1.6 billion.
What is CRISPR Therapeutics's book value?
CRISPR Therapeutics's shareholders' equity (book value) was $1.9 billion at the end of fiscal 2025, or $21.37 per share.
What is CRISPR Therapeutics's current ratio?
CRISPR Therapeutics had current assets of $2.0 billion and current liabilities of $149.1 million, a current ratio of 13.32 (it can cover its short-term obligations).